PATENT CLAIM ANALYSIS

Application Number: 16003855
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "449000"]

Abstract:
The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

Claim (Index 11):
The transdermal therapeutic system according to  claim 2 ,\n wherein the polysiloxane is a mixture of an amine-resistant and a non-amine-resistant dimethylpolysiloxane, where the non-amine-resistant dimethylpolysiloxane is present in the mixture at up to 40% by weight; wherein the at least one carboxylic acid diffuses into the skin more quickly than does the active ingredient buprenorphine and where the at least one carboxylic acid is liquid at skin temperature; and wherein the amount of the dispersed solution in the matrix layer is up to 40% by weight.

Metadata:
- Claim Count in Document: 75.0
- Percentile: 94.0
- Lexical Diversity: 1.52273
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12515848', '14992122', '13885958', '12301244', '14893020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.726210007320361
- 35 USC 102 Novelty (BERT): 0.5542231324218461
- Combined Prediction Score: 0.7090113198305096
- Mean Citation Score: 239.250206
- Max Citation Score: 412.56885
- Similarity Product: 371.54315993127824

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test